Equities Analysts Offer Predictions for HTG Molecular Diagnostics Inc’s Q3 2019 Earnings (NASDAQ:HTGM)

Share on StockTwits

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) – Equities research analysts at Svb Leerink lifted their Q3 2019 earnings per share (EPS) estimates for shares of HTG Molecular Diagnostics in a research report issued on Tuesday, August 6th. Svb Leerink analyst P. Souda now expects that the medical research company will earn ($0.14) per share for the quarter, up from their prior estimate of ($0.16). Svb Leerink also issued estimates for HTG Molecular Diagnostics’ Q1 2020 earnings at ($0.08) EPS, Q2 2020 earnings at ($0.11) EPS, Q3 2020 earnings at ($0.08) EPS, Q4 2020 earnings at ($0.11) EPS, FY2020 earnings at ($0.39) EPS and FY2021 earnings at ($0.09) EPS.

HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). HTG Molecular Diagnostics had a negative net margin of 79.96% and a negative return on equity of 95.77%. The business had revenue of $5.80 million during the quarter, compared to analysts’ expectations of $5.54 million.

Other equities analysts also recently issued reports about the company. ValuEngine upgraded HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded HTG Molecular Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright decreased their target price on HTG Molecular Diagnostics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $5.00 target price on shares of HTG Molecular Diagnostics in a research report on Tuesday, May 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $5.20.

Shares of HTG Molecular Diagnostics stock opened at $1.11 on Friday. The firm has a 50-day simple moving average of $1.50. HTG Molecular Diagnostics has a 52 week low of $1.04 and a 52 week high of $5.46. The stock has a market capitalization of $36.74 million, a P/E ratio of -1.85 and a beta of 1.55. The company has a quick ratio of 6.05, a current ratio of 3.49 and a debt-to-equity ratio of 0.87.

Large investors have recently bought and sold shares of the stock. Perkins Capital Management Inc. lifted its position in shares of HTG Molecular Diagnostics by 37.8% in the first quarter. Perkins Capital Management Inc. now owns 619,920 shares of the medical research company’s stock worth $1,550,000 after buying an additional 169,970 shares in the last quarter. FMR LLC lifted its position in shares of HTG Molecular Diagnostics by 0.6% in the fourth quarter. FMR LLC now owns 3,607,849 shares of the medical research company’s stock worth $9,164,000 after buying an additional 19,804 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of HTG Molecular Diagnostics in the fourth quarter worth about $27,000. BlackRock Inc. lifted its position in shares of HTG Molecular Diagnostics by 16.4% in the fourth quarter. BlackRock Inc. now owns 88,565 shares of the medical research company’s stock worth $225,000 after buying an additional 12,448 shares in the last quarter. Finally, Cowen Prime Services LLC purchased a new stake in shares of HTG Molecular Diagnostics in the first quarter worth about $50,000. Institutional investors own 44.98% of the company’s stock.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.

Featured Article: Federal Reserve

Earnings History and Estimates for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

VANGUARD SCOTTS/VANGUARD RUSSELL 20  Shares Acquired by Wells Fargo & Company MN
VANGUARD SCOTTS/VANGUARD RUSSELL 20 Shares Acquired by Wells Fargo & Company MN
$1.41 EPS Expected for Burlington Stores Inc  This Quarter
$1.41 EPS Expected for Burlington Stores Inc This Quarter
$1.79 Billion in Sales Expected for Burlington Stores Inc  This Quarter
$1.79 Billion in Sales Expected for Burlington Stores Inc This Quarter
Public Employees Retirement System of Ohio Has $2.94 Million Holdings in Wyndham Destinations
Public Employees Retirement System of Ohio Has $2.94 Million Holdings in Wyndham Destinations
Public Employees Retirement System of Ohio Buys Shares of 34,182 Guardant Health Inc
Public Employees Retirement System of Ohio Buys Shares of 34,182 Guardant Health Inc
Public Employees Retirement System of Ohio Grows Position in Empire State Realty Trust Inc
Public Employees Retirement System of Ohio Grows Position in Empire State Realty Trust Inc


© 2006-2019 Ticker Report